BACKGROUND: There are inherent conceptual problems in investigating the pharmacodynamics of cancer drugs in vivo. One of the few possible approaches is serial biopsies in patients. However, this type of research is severely limited by methodological and ethical constraints. MATERIALS AND METHODS: A modified 3-dimensional tissue culture technique was used to culture human tumor samples, which had been collected during routine cancer operations. Twenty tumor samples of patients with non-small cell lung cancer (NSCLC) were cultured ex vivo for 120 h and treated with mitomycin C, taxotere and cisplatin. The cytotoxic activity of the anticancer agents was quantified by assessing the metabolic activity of treated tumor cultures and various assays of apoptosis and gene expression were performed. RESULTS: The proliferative activity of the tissue was maintained in culture as assessed by Ki-67 staining. Mitomycin C, cisplatin and taxotere reduced the metabolic activity of the tumor tissue cultures by 51%, 29% and 20%, respectively, at 120 h. The decrease in metabolic activity corresponded to the induction of apoptosis as demonstrated by the typical morphological changes, such as chromatin condensation and nuclear fragmentation. In addition, activated caspase-3 could be verified in apoptotic cells by immunohistochemistry. To verify functional aspects of apoptosis, the induction of chemotherapy-induced cell death was inhibited with the caspase inhibitor z-VAD.fmk. RNA was extracted from the tissue cultures after 120 h of ex vivo drug treatment and was of sufficient quality to allow quantitative PCR. CONCLUSION: The 3-dimensional ex vivo culture technique is a useful method to assess the molecular effects of pharmacological interventions in human cancer samples in vitro. This culture technique could become an important tool for drug development and for the prediction of in vivo drug efficacy.
BACKGROUND: There are inherent conceptual problems in investigating the pharmacodynamics of cancer drugs in vivo. One of the few possible approaches is serial biopsies in patients. However, this type of research is severely limited by methodological and ethical constraints. MATERIALS AND METHODS: A modified 3-dimensional tissue culture technique was used to culture humantumor samples, which had been collected during routine cancer operations. Twenty tumor samples of patients with non-small cell lung cancer (NSCLC) were cultured ex vivo for 120 h and treated with mitomycin C, taxotere and cisplatin. The cytotoxic activity of the anticancer agents was quantified by assessing the metabolic activity of treated tumor cultures and various assays of apoptosis and gene expression were performed. RESULTS: The proliferative activity of the tissue was maintained in culture as assessed by Ki-67 staining. Mitomycin C, cisplatin and taxotere reduced the metabolic activity of the tumor tissue cultures by 51%, 29% and 20%, respectively, at 120 h. The decrease in metabolic activity corresponded to the induction of apoptosis as demonstrated by the typical morphological changes, such as chromatin condensation and nuclear fragmentation. In addition, activated caspase-3 could be verified in apoptotic cells by immunohistochemistry. To verify functional aspects of apoptosis, the induction of chemotherapy-induced cell death was inhibited with the caspase inhibitor z-VAD.fmk. RNA was extracted from the tissue cultures after 120 h of ex vivo drug treatment and was of sufficient quality to allow quantitative PCR. CONCLUSION: The 3-dimensional ex vivo culture technique is a useful method to assess the molecular effects of pharmacological interventions in humancancer samples in vitro. This culture technique could become an important tool for drug development and for the prediction of in vivo drug efficacy.
Authors: Adam C ElNaggar; Uksha Saini; Shan Naidu; Ross Wanner; Millie Sudhakar; John Fowler; Masaki Nagane; Periannan Kuppusamy; David E Cohn; Karuppaiyah Selvendiran Journal: Cancer Biol Ther Date: 2016-10-02 Impact factor: 4.742
Authors: Wei Bin Fang; Min Yao; Iman Jokar; Nabil Alhakamy; Cory Berkland; Jin Chen; Dana Brantley-Sieders; Nikki Cheng Journal: Breast Cancer Res Treat Date: 2015-03-06 Impact factor: 4.872
Authors: Nicholas Willumsen; Cecilie L Bager; Anne-Christine Bay-Jensen; Stephanie N Kehlet; Henrik Harling; Diana J Leeming; Morten A Karsdal; Lars N Jorgensen Journal: Oncol Lett Date: 2017-03-23 Impact factor: 2.967
Authors: Uksha Saini; Shan Naidu; Adam C ElNaggar; Hemant Kumar Bid; John J Wallbillich; Kristin Bixel; Chelsea Bolyard; Adrian A Suarez; Balveen Kaur; Periannan Kuppusamy; John Hays; Paul J Goodfellow; David E Cohn; Karuppaiyah Selvendiran Journal: Oncogene Date: 2016-06-13 Impact factor: 9.867
Authors: Dagmar S Lang; Daniel Droemann; Holger Schultz; Detlev Branscheid; Christian Martin; Anne R Ressmeyer; Peter Zabel; Ekkehard Vollmer; Torsten Goldmann Journal: Respir Res Date: 2007-06-14
Authors: Ian R Powley; Meeta Patel; Gareth Miles; Howard Pringle; Lynne Howells; Anne Thomas; Catherine Kettleborough; Justin Bryans; Tim Hammonds; Marion MacFarlane; Catrin Pritchard Journal: Br J Cancer Date: 2020-01-02 Impact factor: 7.640